Affiliation:
1. Republican Center for Prevention and Control of AIDS and Infectious Diseases;Pavlov First State Medical University
2. Pavlov First State Medical University
3. Pavlov First State Medical University; Smorodintsev Research Institute of Influenza
Abstract
The Aim: to characterize the immune response to the influenza vaccine in patients with HIV infection with different degrees of immunosuppression.Materials and methods. 171 HIV-infected adult patients with the different degrees of immunodeficiency and 50 HIV-uninfected persons (control group) were vaccinated against influenza. A single dose of trivalent polymer-subunit vaccine containing adjuvant was administered intramuscularly. The blood titer of antibodies to influenza virus antigens A/H1N1/California/, A/H3N2/Hong Kong/, B/Brisbane/ in the hemagglutination inhibition reaction was determined before vaccination and 21 and 180 days after. The average geometric titers of antibodies were compared between groups of HIV-infected patients with the different degrees of immunosuppression and the control group.Results. Тhe mean geometric antibody titers increase among HIV-infected with different degrees of immunodeficiency was below 2,0 and the seroconversion rate was below 8,0% for all influenza virus antigens on 21 and 180 days after vaccination. At the same time, during follow-up period in patients with level less than 200 cells /μl of CD4+lymphocytes in blood, the seroconversion index was equal to 0%. The rate of seroprotection to all antigens before vaccination in HIVinfected patients with the different degrees of immunosuppression was above 90%. Naturally, during follow-up period, more than 95,0% of vaccinated patients determined the protective level of antibodies to antigen A /H1N1 and 100,0% of patients to antigen A/H3N2 and B, without reducing this index to the day-180 of observation. Persons from control group showed a sufficient level of seroconversion and seroprotection, corresponding to the criteria of immunogenicity for all antigens of the influenza virus. Conclusion: a single immunization of influenza vaccine does not cause a sufficient degree of serological response in patients with HIV infection, regardless of the severity of immunodeficiency. Seroprotection in case of its developing persists up to 180 day after vaccination.
Publisher
Baltic Medical Education Center
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,Immunology
Reference22 articles.
1. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossijskoj Federacii v 2018 godu: Gosudarstvennyj doklad. Moscow: Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebitelej i blagopoluchiya cheloveka, 2019: 254 [Elektronnyj resurs] (In Russ.)]. https://rospotrebnadzor.ru/upload/iblock/798/gosudarstvennyy-doklad-o-sostoyanii-sanitarno_epidemiologicheskogo-blagopoluchiya-naseleniya-v-rossiyskoy-federatsii-v-2018-godu.pdf
2. World Health Organization. WHO launches new global influenza strategy (Electronic resource). URL: https://www.who.int/newsroom/detail/11-03-2019-who-launches-new-global-influenza-strategy
3. CDC. Disease Burden of Influenza (Electronic resource). URL: https://www.cdc.gov/flu/about/burden/index.html
4. World Health Organization. Vaccine position papers (Electronic resource). 2019. URL: http://www.who.int/immunization/documents/positionpapers/en/
5. Sheth A.N., Althoff K.N., Brooks J.T. Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature // Clin. Infect. Dis. 2011. Vol. 52, No. 2. Р. 219–227. DOI: 10.1093/cid/ciq110.